@article{ThomannSchneiderCyranetal.2021, author = {Thomann, Anna Sophie and Schneider, Theresa and Cyran, Laura and Eckert, Ina Nathalie and Kerstan, Andreas and Lutz, Manfred B.}, title = {Conversion of Anergic T Cells Into Foxp3\(^-\) IL-10\(^+\) Regulatory T Cells by a Second Antigen Stimulus In Vivo}, series = {Frontiers in Immunology}, volume = {12}, journal = {Frontiers in Immunology}, issn = {1664-3224}, doi = {10.3389/fimmu.2021.704578}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-241429}, year = {2021}, abstract = {T cell anergy is a common mechanism of T cell tolerance. However, although anergic T cells are retained for longer time periods in their hosts, they remain functionally passive. Here, we describe the induction of anergic CD4\(^+\) T cells in vivo by intravenous application of high doses of antigen and their subsequent conversion into suppressive Foxp3\(^-\) IL-10\(^+\) Tr1 cells but not Foxp3\(^+\) Tregs. We describe the kinetics of up-regulation of several memory-, anergy- and suppression-related markers such as CD44, CD73, FR4, CD25, CD28, PD-1, Egr-2, Foxp3 and CTLA-4 in this process. The conversion into suppressive Tr1 cells correlates with the transient intracellular CTLA-4 expression and required the restimulation of anergic cells in a short-term time window. Restimulation after longer time periods, when CTLA-4 is down-regulated again retains the anergic state but does not lead to the induction of suppressor function. Our data require further functional investigations but at this stage may suggest a role for anergic T cells as a circulating pool of passive cells that may be re-activated into Tr1 cells upon short-term restimulation with high and systemic doses of antigen. It is tentative to speculate that such a scenario may represent cases of allergen responses in non-allergic individuals.}, language = {en} } @article{BrieseSendtner2021, author = {Briese, Michael and Sendtner, Michael}, title = {Keeping the balance: the noncoding RNA 7SK as a master regulator for neuron development and function}, series = {BioEssays}, volume = {43}, journal = {BioEssays}, number = {8}, doi = {10.1002/bies.202100092}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-256613}, year = {2021}, abstract = {The noncoding RNA 7SK is a critical regulator of transcription by adjusting the activity of the kinase complex P-TEFb. Release of P-TEFb from 7SK stimulates transcription at many genes by promoting productive elongation. Conversely, P-TEFb sequestration by 7SK inhibits transcription. Recent studies have shown that 7SK functions are particularly important for neuron development and maintenance and it can thus be hypothesized that 7SK is at the center of many signaling pathways contributing to neuron function. 7SK activates neuronal gene expression programs that are key for terminal differentiation of neurons. Proteomics studies revealed a complex protein interactome of 7SK that includes several RNA-binding proteins. Some of these novel 7SK subcomplexes exert non-canonical cytosolic functions in neurons by regulating axonal mRNA transport and fine-tuning spliceosome production in response to transcription alterations. Thus, a picture emerges according to which 7SK acts as a multi-functional RNA scaffold that is integral for neuron homeostasis.}, language = {en} } @article{BarreaVetraniAltierietal.2021, author = {Barrea, Luigi and Vetrani, Claudia and Altieri, Barbara and Verde, Ludovica and Savastano, Silvia and Colao, Annamaria and Muscogiuri, Giovanna}, title = {The importance of being a 'lark' in post-menopausal women with obesity: a ploy to prevent type 2 diabetes mellitus?}, series = {Nutrients}, volume = {13}, journal = {Nutrients}, number = {11}, issn = {2072-6643}, doi = {10.3390/nu13113762}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-248572}, year = {2021}, abstract = {Chronotype is defined as the behavioral manifestation of circadian rhythms related to the external light-dark cycle. Evening chronotype has been associated with an increased risk of developing cardiometabolic diseases in obesity. Menopause is a lifestage associated with an increased risk of developing cardiometabolic diseases and a change in circadian rhythmicity compared to pre-menopause. However, the prevalence of chronotype categories in menopause and their role in determining menopause-related cardiometabolic risk, mostly in obesity, have not been investigated. Thus, we aimed to investigate the prevalence of chronotype categories in post-menopausal women with obesity and their role in menopause-related cardiometabolic risk. In this cross-sectional study we enrolled 49 pre-menopausal and 74 post-menopausal women with obesity. Anthropometric parameters, lifestyle habits, adherence to the Mediterranean Diet (MD), sleep quality, chronotype and the presence of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) were studied. No significance differences were detected in terms of lifestyle and adherence to the MD between pre- and post-menopausal women. Chronotype was classified as morning in 66 (53.6\%), evening in 20 (16.3\%) and intermediate in 37 (30.1\%) women. In addition, pre-menopausal women with obesity showed a significantly higher chance to have an intermediate chronotype (OR = 2.21, 95\% CI 1.28-3.83; p = 0.004), whereas post-menopausal women with obesity showed a trend to have a higher morning chronotype (OR = 1.42, 95\% CI 0.98-2.06; p = 0.051), although this did not reach statistical significance. No significant differences were detected in terms of prevalence of evening chronotype between the two groups. However, the evening chronotype had a significantly higher risk to have T2DM compared to the morning (OR = 17.29, 95\% CI 2.40-124.27; p = 0.005) and intermediate chronotypes (OR = 30.86, 95\% CI 2.05-464.32; p = 0.013) in both pre- and post-menopausal women with obesity. In conclusion, the intermediate chronotype was significantly more prevalent in pre-menopausal women with obesity compared to post-menopausal women. Evening chronotype was associated to T2DM in both pre- and post-menopause. These results support the importance of including the assessment of chronotype in the management of women with obesity in post-menopause.}, language = {en} } @article{BlumTaskinShanetal.2021, author = {Blum, Carina and Taskin, Mehmet Berat and Shan, Junwen and Schilling, Tatjana and Schlegelmilch, Katrin and Teßmar, J{\"o}rg and Groll, J{\"u}rgen}, title = {Appreciating the First Line of the Human Innate Immune Defense: A Strategy to Model and Alleviate the Neutrophil Elastase-Mediated Attack toward Bioactivated Biomaterials}, series = {Small}, volume = {17}, journal = {Small}, number = {13}, doi = {10.1002/smll.202007551}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-257691}, year = {2021}, abstract = {Biointerface engineering is a wide-spread strategy to improve the healing process and subsequent tissue integration of biomaterials. Especially the integration of specific peptides is one promising strategy to promote the regenerative capacity of implants and 3D scaffolds. In vivo, these tailored interfaces are, however, first confronted with the innate immune response. Neutrophils are cells with pronounced proteolytic potential and the first recruited immune cells at the implant site; nonetheless, they have so far been underappreciated in the design of biomaterial interfaces. Herein, an in vitro approach is introduced to model and analyze the neutrophil interaction with bioactivated materials at the example of nano-bioinspired electrospun surfaces that reveals the vulnerability of a given biointerface design to the contact with neutrophils. A sacrificial, transient hydrogel coating that demonstrates optimal protection for peptide-modified surfaces and thus alleviates the immediate cleavage by neutrophil elastase is further introduced.}, language = {en} } @article{RajendranBoettigerStadelmannetal.2021, author = {Rajendran, Ranjithkumar and B{\"o}ttiger, Gregor and Stadelmann, Christine and Karnati, Srikanth and Berghoff, Martin}, title = {FGF/FGFR pathways in multiple sclerosis and in its disease models}, series = {Cells}, volume = {10}, journal = {Cells}, number = {4}, issn = {2073-4409}, doi = {10.3390/cells10040884}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236594}, year = {2021}, abstract = {Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) affecting more than two million people worldwide. In MS, oligodendrocytes and myelin sheaths are destroyed by autoimmune-mediated inflammation, while remyelination is impaired. Recent investigations of post-mortem tissue suggest that Fibroblast growth factor (FGF) signaling may regulate inflammation and myelination in MS. FGF2 expression seems to correlate positively with macrophages/microglia and negatively with myelination; FGF1 was suggested to promote remyelination. In myelin oligodendrocyte glycoprotein (MOG)\(_{35-55}\)-induced experimental autoimmune encephalomyelitis (EAE), systemic deletion of FGF2 suggested that FGF2 may promote remyelination. Specific deletion of FGF receptors (FGFRs) in oligodendrocytes in this EAE model resulted in a decrease of lymphocyte and macrophage/microglia infiltration as well as myelin and axon degeneration. These effects were mediated by ERK/Akt phosphorylation, a brain-derived neurotrophic factor, and downregulation of inhibitors of remyelination. In the first part of this review, the most important pharmacotherapeutic principles for MS will be illustrated, and then we will review recent advances made on FGF signaling in MS. Thus, we will suggest application of FGFR inhibitors, which are currently used in Phase II and III cancer trials, as a therapeutic option to reduce inflammation and induce remyelination in EAE and eventually MS.}, language = {en} } @article{WernerHiguchiPomperetal.2021, author = {Werner, Rudolf A. and Higuchi, Takahiro and Pomper, Martin G. and Rowe, Steven P.}, title = {Theranostics in oncology — thriving, now more than ever}, series = {Diagnostics}, volume = {11}, journal = {Diagnostics}, number = {5}, issn = {2075-4418}, doi = {10.3390/diagnostics11050805}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236662}, year = {2021}, abstract = {Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.}, language = {en} } @article{ZieglerRadtkeVitaleetal.2021, author = {Ziegler, Georg C. and Radtke, Franziska and Vitale, Maria Rosaria and Preuße, Andr{\´e} and Klopocki, Eva and Herms, Stefan and Lesch, Klaus-Peter}, title = {Generation of multiple human iPSC lines from peripheral blood mononuclear cells of two SLC2A3 deletion and two SLC2A3 duplication carriers}, series = {Stem Cell Research}, volume = {56}, journal = {Stem Cell Research}, doi = {10.1016/j.scr.2021.102526}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-264696}, year = {2021}, abstract = {Copy number variants of SLC2A3, which encodes the glucose transporter GLUT3, are associated with several neuropsychiatric and cardiac diseases. Here, we report the successful reprogramming of peripheral blood mononuclear cells from two SLC2A3 duplication and two SLC2A3 deletion carriers and subsequent generation of two transgene-free iPSC clones per donor by Sendai viral transduction. All eight clones represent bona fide hiPSCs with high expression of pluripotency genes, ability to differentiate into cells of all three germ layers and normal karyotype. The generated cell lines will be helpful to enlighten the role of glucometabolic alterations in pathophysiological processes shared across organ boundaries.}, language = {en} } @article{RauschenbergerKnorrPisanietal.2021, author = {Rauschenberger, Lisa and Knorr, Susanne and Pisani, Antonio and Hallett, Mark and Volkmann, Jens and Ip, Chi Wang}, title = {Second hit hypothesis in dystonia: Dysfunctional cross talk between neuroplasticity and environment?}, series = {Neurobiology of Disease}, volume = {159}, journal = {Neurobiology of Disease}, doi = {10.1016/j.nbd.2021.105511}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265028}, year = {2021}, abstract = {One of the great mysteries in dystonia pathophysiology is the role of environmental factors in disease onset and development. Progress has been made in defining the genetic components of dystonic syndromes, still the mechanisms behind the discrepant relationship between dystonic genotype and phenotype remain largely unclear. Within this review, the preclinical and clinical evidence for environmental stressors as disease modifiers in dystonia pathogenesis are summarized and critically evaluated. The potential role of extragenetic factors is discussed in monogenic as well as adult-onset isolated dystonia. The available clinical evidence for a "second hit" is analyzed in light of the reduced penetrance of monogenic dystonic syndromes and put into context with evidence from animal and cellular models. The contradictory studies on adult-onset dystonia are discussed in detail and backed up by evidence from animal models. Taken together, there is clear evidence of a gene-environment interaction in dystonia, which should be considered in the continued quest to unravel dystonia pathophysiology.}, language = {en} } @article{HoseSchrederHefneretal.2021, author = {Hose, Dorothea and Schreder, Martin and Hefner, Jochen and Bittrich, Max and Danhof, Sophia and Strifler, Susanne and Krauth, Maria-Theresa and Schoder, Renate and Gisslinger, Bettina and Einsele, Hermann and Gisslinger, Heinz and Knop, Stefan}, title = {Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers}, series = {Journal of Cancer Research and Clinical Oncology}, volume = {147}, journal = {Journal of Cancer Research and Clinical Oncology}, issn = {0171-5216}, doi = {10.1007/s00432-020-03323-6}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-235762}, pages = {205-212}, year = {2021}, abstract = {Background The anti-SLAMF7 monoclonal antibody, elotuzumab (elo), plus lenalidomide (len) and dexamethasone (dex) is approved for relapsed/refractory MM in the U.S. and Europe. Recently, a small phase 2 study demonstrated an advantage in progression-free survival (PFS) for elo plus pomalidomide (pom)/dex compared to pom/dex alone and resulted in licensing of this novel triplet combination, but clinical experience is still limited. Purpose To analyze the efficacy and safety of elo/pom/dex in a "real world" cohort of patients with advanced MM, we queried the databases of the university hospitals of W{\"u}rzburg and Vienna. Findings We identified 22 patients with a median number of five prior lines of therapy who received elo/pom/dex prior to licensing within an early access program. Patients received a median number of 5 four-week treatment cycles. Median PFS was 6.4 months with 12-month and 18-month PFS rates of 35\% and 28\%, respectively. The overall response rate was 50\% and 64\% of responding patients who achieved a longer PFS with elo/pom/dex compared to their most recent line of therapy. Objective responses were also seen in five patients who had been pretreated with pomalidomide. Low tumor burden was associated with improved PFS (13.5 months for patients with ISS stage I/II at study entry v 6.4 months for ISS III), although this difference did not reach statistical significance. No infusion-related reactions were reported. The most frequent grade 3/4 adverse events were neutropenia and pneumonia. Conclusion Elo/pom/dex is an active and well-tolerated regimen in highly advanced MM even after pretreatment with pomalidomide.}, language = {en} } @article{TerekhovElabyadSchreiber2021, author = {Terekhov, Maxim and Elabyad, Ibrahim A. and Schreiber, Laura M.}, title = {Global optimization of default phases for parallel transmit coils for ultra-high-field cardiac MRI}, series = {PLoS One}, volume = {16}, journal = {PLoS One}, number = {8}, doi = {10.1371/journal.pone.0255341}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265737}, year = {2021}, abstract = {The development of novel multiple-element transmit-receive arrays is an essential factor for improving B\(_1\)\(^+\) field homogeneity in cardiac MRI at ultra-high magnetic field strength (B\(_0\) > = 7.0T). One of the key steps in the design and fine-tuning of such arrays during the development process is finding the default driving phases for individual coil elements providing the best possible homogeneity of the combined B\(_1\)\(^+\)-field that is achievable without (or before) subject-specific B\(_1\)\(^+\)-adjustment in the scanner. This task is often solved by time-consuming (brute-force) or by limited efficiency optimization methods. In this work, we propose a robust technique to find phase vectors providing optimization of the B-1-homogeneity in the default setup of multiple-element transceiver arrays. The key point of the described method is the pre-selection of starting vectors for the iterative solver-based search to maximize the probability of finding a global extremum for a cost function optimizing the homogeneity of a shaped B\(_1\)\(^+\)-field. This strategy allows for (i) drastic reduction of the computation time in comparison to a brute-force method and (ii) finding phase vectors providing a combined B\(_1\)\(^+\)-field with homogeneity characteristics superior to the one provided by the random-multi-start optimization approach. The method was efficiently used for optimizing the default phase settings in the in-house-built 8Tx/16Rx arrays designed for cMRI in pigs at 7T.}, language = {en} }